Page 86 - Michael Erman News Today

How South Korea turbocharged specialty syringe production for COVID-19 vaccines Reuters 2 hrs ago By Sangmi Cha By Sangmi Cha SEOUL (Reuters) - It was 7:30 a.m. on Christmas Eve when Cha Jung-hoon, South Koreas deputy minister for small businesses, got a call from his boss to make an urgent three-hour car trip to visit syringe maker Poonglim Pharmatech. The brief: work out how the government could convince and aid Poonglim, which had only about 80 employees, to rapidly scale...

U.S. parents begin to ask: Should my child get a COVID-19 shot? Reuters 1 hr ago © Reuters/SHAWN ROCCO/DUKE HEALTH Clinical trial for children for COVID-19 vaccines By Gabriella Borter and Michael Erman (Reuters) - Tristen Sweeten, a 34-year-old nurse in Utah, hopes her three children will receive Modernas COVID-19 vaccine through its pediatric clinical trial. The sooner the better, she said, for their safety and the greater goal of ending the pandemic. Angie Ankoma, a 45-year-old Black ...

Merck & Co Inc (MRK.N) on Thursday said it plans a large study of what could become the first pill to target the coronavirus in people at risk of severe COVID-19, but will no longer pursue use of the experimental antiviral drug in hospitalized patients.

By Michael Erman NEW YORK (Reuters) - Moderna Inc said on Tuesday that its COVID-19 vaccine still showed strong protection against the illness six months after people received their second shot, with efficacy of more than 90 percent against all cases of COVID-19 and more than 95 percent against severe COVID-19. The vaccine maker, which will be updating investors on the progress of its vaccines at an event on Wednesday, said the six-month follow-up of its original late-stage study of the vacc...

U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine after six women under 50 given the shot developed rare blood clots, dealing a fresh setback to efforts to tackle the pandemic.

U.S. pauses use of J&J COVID-19 vaccine over rare blood clots, rollout delayed in Europe By Michael Erman and Manas Mishra Reuters (Reuters) - U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnsons COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic. Johnson & Johnson (J&J) said it would delay rollout of the vaccine to Europe, a ...

U.S. pauses use of J&J vaccine over rare blood clots, rollout delayed in Europe By Michael Erman and Manas Mishra Reuters (Reuters) - U.S. federal health agencies on Tuesday recommended pausing use of Johnson & Johnsons COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic. Johnson & Johnson said it would delay rollout of the vaccine to Europe, a week after regulato...

U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine for at least a few days after six women

10 Apr 2021 / 09:00 H. By Carl ODonnell April 1 (Reuters) - Pfizer Inc and BioNTech said on Thursday their COVID-19 vaccine is around 91% effective at preventing the disease, citing updated trial data that included participants inoculated for up to six months. The shot was also 100% effective in preventing illness among trial participants in South Africa, where a new variant called B1351 is dominant, although the number of those participants was relatively small at 800. While the new overall e...

10 Apr 2021 / 09:00 H. (Adds BioNTechs development strategy to address variants) By Carl ODonnell April 1 (Reuters) - Pfizer Inc and BioNTech said on Thursday their COVID-19 vaccine is around 91% effective at preventing the disease, citing updated trial data that included participants inoculated for up to six months. The shot was also 100% effective in preventing illness among trial participants in South Africa, where a new variant called B1351 is dominant, although that rate was derived from ...